Additional file 5: of HDAC2 depletion promotes osteosarcoma’s stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy

Figure S3. Analyses of EMT related markers on Saos2 and MG63 cell lines after VPA and DAC treatment. (a) Real-time PCR for SLUG, TWIST, Vimentin E-cadherin and Osteocalcin showing an increase of SLUG mRNA levels in MG63 and Saos2 cells following VPA and combination treatment, a strong increase of TWIST mRNA levels in both cell lines following VPA treatment and an increase of E-cadherin mRNA after DAC treatments. Vimentin mRNA levels did not change. Osteocalcin mRNA levels decreased in both cell lines; (b) Expression of CD324, vimentin and osteocalcin in Saos2 and MG63 cell lines after VPA and DAC treatment analysed by flow cytometry. CD324, Vimentin and Osteocalcin did not change after drug treatment compared to untreated cells. * p < 0.005, ** p < 0.001, *** p < 0.0001 compared to the untreated cells. (TIF 8966 kb